ECMO for COVID-19 patients in Europe and Israel

Le résumé fourni par la source

As of October 17th the novel coronavirus (SARS-CoV-2) caused a pandemic disease (coronavirus disease 2019, COVID-19) 40 million people worldwide, with almost one million deaths [1]. Although most patients have an uncomplicated clinical course, the more severe forms of COVID-19 require hospitalization and intensive care unit admission [2]. Conventional high-flow oxygen therapy, non-invasive and/or invasive mechanical ventilation, often in combination with pronepositioning, have all been reported to be effective in the majority of patients [2]. However, in severe cases, life-threatening, refractory hypoxemia may occur [2]. Secondary infections, myocardial disease involvement and a hypercoaguable state with/without pulmonary embolism may also contribute to the complexity of treating these critically ill patients [3–5]. In such cases rescue therapy may be required. The World Health Organization (WHO) [6], the Extracorporeal Life Support Organization (www.elso.org) and others have advocated the use of extracorporeal membrane oxygenation (ECMO) for patients with severe cardiorespiratory failure. Few patients in China received ECMO support in the early phase of the pandemic and the mortality rate among these patients was high [7]. Initial experience with COVID-19 in Europe was similar as the high number of critically ill patients disrupted usual care pathways and stretched hospital resources [2]. There was probably some hesitation to provide a form of support which is considered highly resource consuming. However, despite the rapid growth in the number of critically ill COVID-19 patients in Europe, over time an unexpectedly high number of severely compromised patients were considered eligible for ECMO support. At this time the Steering Committee of the European chapter of the Extracorporeal Life Support Organization (Euro-ELSO) initiated prospective data collection among European and Israeli centres with the intention of providing near real-time information on ECMO use in COVID-19. The study was approved by the Maastricht University Ethical Committee (coordinating center) and is registered under ClinicalTrials.gov identifier: NCT04366921. Data are collected weekly and reported anonymously through the Euro-ELSO website https://www.euroelso.net/covid-19/covid-19-survey/. This voluntary study includes basic data on patients ́ age and gender, the details of their ECMO treatment and real-time status (i.e., ongoing, successfully weaned, or died). Since March 15th, 2020, 177 centres from Europe and Israel have joined the study, routinely reporting on the ECMO support they provide to COVID-19 patients. The mean annual number of cases treated with ECMO in the participating centres before the pandemic (2019) was 55. The number of COVID-19 patients has increased rapidly each week reaching 1531 treated patients as of September 14th. The greatest number of cases has been reported from France (n = 385), UK (n = 193), Germany (n = 176), Spain (n = 166), and Italy (n = 136) (See Supplementary Fig. 1). The mean age of treated patients was 52.6 years (range 16–80), 79% were male. The ECMO configuration used was VV in 91% of cases, VA in 5% and other in 4%. The mean PaO2 before ECMO implantation was 65 mmHg. The mean duration of ECMO support thus far has been 18 days and the mean ICU length of stay of these patients was 33 days. As of the 14th September, overall 841 patients have been weaned from ECMO support, 601 died during ECMO support, 71 died after withdrawal of ECMO, 79 are still receiving ECMO support and for 10 patients status n.a. (Fig. 1).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.